tiprankstipranks
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA

Centessa Pharmaceuticals (CNTA) Income Statement

71 Followers

Centessa Pharmaceuticals Income Statement

Last quarter (Q1 2024), Centessa Pharmaceuticals's total revenue was $88.00K, an increase of Infinity% from the same quarter last year. In Q1, Centessa Pharmaceuticals's net income was $-38.05M. See Centessa Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20
Total Revenue
$ 88.00K--$ 0.00
Cost of Revenue
----
Gross Profit
$ 88.00K---
Operating Expense
$ 172.19M$ 208.30M$ 374.08M$ 10.44M
Operating Income
$ -172.19M$ -212.26M$ -374.08M$ -10.44M
Net Non Operating Interest Income Expense
$ 269.00K$ -7.03M$ -1.17M$ -378.00K
Other Income Expense
$ 6.09M$ -2.34M$ 5.70M$ 155.00K
Pretax Income
$ -178.01M$ -216.95M$ -380.96M$ -10.66M
Tax Provision
$ -25.74M$ -747.00K$ 114.00K-
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -152.29M$ -216.21M$ -381.07M$ -10.66M
Basic EPS
$ -1.57$ -2.31$ -5.07$ -0.15
Diluted EPS
$ -1.57$ -2.31$ -5.07$ -0.15
Basic Average Shares
$ 386.64M$ 93.40M$ 75.17M$ 70.89M
Diluted Average Shares
$ 386.64M$ 93.40M$ 75.17M$ 70.89M
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 172.19M$ 208.30M$ 374.08M$ 10.44M
Net Income From Continuing And Discontinued Operation
$ -152.29M$ -216.21M$ -381.07M$ -10.66M
Normalized Income
$ -154.50M--$ -10.66M
Interest Expense
---$ 378.00K
EBIT
$ -170.68M$ -209.68M$ -379.79M$ -10.29M
EBITDA
$ -169.88M$ -209.55M$ -379.75M$ -10.29M
Currency in USD

Centessa Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis